ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years
Bin Lan
Matched on ORCID iD 0000-0001-9878-5106; OpenAlex author ID A5051875334. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2019: 2 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers
Papers 7
- Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathw… Co-author DOI 10.1038/s41598-025-95766-5↗
- Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Co-author DOI 10.3390/cancers17193181↗
- Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Co-author DOI 10.1038/s41420-024-01890-y↗
- CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. First author DOI 10.1186/s13046-022-02443-w↗
- CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Co-author DOI 10.3390/cancers14020326↗
- The Role of Exosomes in Pancreatic Cancer. Co-author DOI 10.3390/ijms20184332↗
- Chemoresistance in Pancreatic Cancer. Co-author DOI 10.3390/ijms20184504↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Robert Grützmann · 7 shared papers, 2019–2025 · strength 1.11
- Paper Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Ca… DOI 10.3390/cancers17193181↗
- Paper Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by… DOI 10.1038/s41598-025-95766-5↗
- Paper Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. DOI 10.1038/s41420-024-01890-y↗
- Christian P. Pilarsky · 7 shared papers, 2019–2025 · strength 1.11
- Paper Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Ca… DOI 10.3390/cancers17193181↗
- Paper Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by… DOI 10.1038/s41598-025-95766-5↗
- Paper Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. DOI 10.1038/s41420-024-01890-y↗
- Nathalie Britzen‐Laurent · 4 shared papers, 2022–2025 · strength 0.64
- Paper Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Ca… DOI 10.3390/cancers17193181↗
- Paper Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. DOI 10.1038/s41420-024-01890-y↗
- Paper CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. DOI 10.3390/cancers14020326↗
- Debabrata Mukhopadhyay · 3 shared papers, 2022–2025 · strength 0.48
- Paper Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by… DOI 10.1038/s41598-025-95766-5↗
- Paper Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. DOI 10.1038/s41420-024-01890-y↗
- Paper CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. DOI 10.1186/s13046-022-02443-w↗
- Andrew Victor Biankin · 3 shared papers, 2022–2025 · strength 0.48
- Paper Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by… DOI 10.1038/s41598-025-95766-5↗
- Paper Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. DOI 10.1038/s41420-024-01890-y↗
- Paper CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. DOI 10.1186/s13046-022-02443-w↗
- Hai Yang · 3 shared papers, 2019–2024 · strength 0.39
- Paper Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. DOI 10.1038/s41420-024-01890-y↗
- Paper CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. DOI 10.1186/s13046-022-02443-w↗
- Paper Chemoresistance in Pancreatic Cancer. DOI 10.3390/ijms20184504↗
- Siyuan Zeng · 3 shared papers, 2019–2022 · strength 0.38
- Nils Cordes · 2 shared papers, 2022–2025 · strength 0.37
- Yanxi Lu · 2 shared papers, 2024–2025 · strength 0.36
- David Kuang-Fu Chang · 2 shared papers, 2022–2025 · strength 0.34
- Shuman Zhang · 2 shared papers, 2022–2024 · strength 0.27
- Hnin Ei Ei Khine · 1 shared paper, 2025 · strength 0.21
- Chatchai Chaotham · 1 shared paper, 2025 · strength 0.21
- Jinping Zhang · 1 shared paper, 2024 · strength 0.15
- Duo Yun · 1 shared paper, 2024 · strength 0.15
- Eva Lentsch · 1 shared paper, 2024 · strength 0.15
- Hang He · 1 shared paper, 2024 · strength 0.15
- Marc P. Stemmler · 1 shared paper, 2024 · strength 0.15
- Hao Yang · 1 shared paper, 2024 · strength 0.15
- Peter J. Bailey · 1 shared paper, 2022 · strength 0.13
- Daniel Schreyer · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.